Clinical trial Recruiting at 1 site Interventional Ages 19 and up

Optimal side-branch stenting strategy for complex coronary bifurcation using drug-coated balloons

Official title: Drug-Coated Balloon Versus Drug-eluting Stent for Treatment of Clinically Relevant Side Branch in Complex Coronary Bifurcation Lesion

Run by Samsung Medical Center · NCT07019350 · Data updated 2026-11-12

This study tests whether starting with two stents or using a drug-coated balloon (DCB)-based hybrid approach works better for adults having PCI for complex coronary bifurcation lesions with an important side branch.

Quick facts

Study typeInterventional
Ages19 Years and up
SexAll
Enrollment520 (estimated)
SponsorSamsung Medical Center
Academic / other
Locations3 sites (Gwangju and 2 other locations)
StatusRecruiting
StartedOctober 22, 2025
Main results expectedDecember 31, 2030
Study endsDecember 31, 2030
Registry record updatedNovember 24, 2025
Trial IDNCT07019350 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥19 years) with acute or chronic coronary syndrome planned for PCI who have de novo true coronary bifurcation lesions with a clinically relevant side branch (Medina 1,1,1; 1,0,1; 0,1,1) with SB lesion length ≥10 mm and meeting the protocol's stenosis/size criteria, and who can give informed consent are ideal candidates.

Probably not a fit

Patients who are hemodynamically unstable, who do not have a true or clinically significant side-branch lesion, who have very small side branches that do not meet size criteria, or who are not PCI candidates are unlikely to benefit from this trial's treatments.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective, multi-center, open-label, randomized controlled superiority trial comparing an upfront two-stent strategy versus an upfront DCB-based hybrid strategy in patients with complex true coronary bifurcation lesions. Eligible lesions are true bifurcations (Medina 1,1,1; 1,0,1; 0,1,1) with side-branch lesion length ≥10 mm and defined severity/size thresholds for left main and non-left main vessels. The study enrolls adults undergoing PCI for acute or chronic coronary syndromes and measures clinical outcomes such as mortality, unplanned repeat revascularization, and stent-related complications. The trial builds on mixed prior results favoring two-stent approaches in more complex lesions and emerging data supporting DCB angioplasty at side branches.

Why it matters

Potential benefit: If successful, the approach could reduce the need for repeat procedures and lower stent-related complications for patients with complex bifurcation lesions.

How similar studies have gone: Previous trials have shown mixed results—some favor upfront two-stent strategies for very complex bifurcations, while recent studies of DCB use at side branches have produced promising but not yet definitive results.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria

* Subject must be at least 19 years of age
* Patients with acute or chronic coronary syndrome intended for percutaneous coronary intervention (PCI)
* Patients with de novo complex coronary bifurcation with clinically relevant side branch. Definition of complex coronary bifurcation with clinically relevant side branch is true bifurcation lesion (Medina 1,1,1 / 1,0,1 / 0,1,1) with side branch lesion length ≥10mm and should meet at least one of the below criteria.

  i. Left main bifurcation with side branch stenosis severity ≥70% by visual estimation ii. Non-left main bifurcation with side branch reference vessel diameter ≥2.75mm and stenosis severity ≥90% by visual estimation
* Subject who can verbally confirm understandings of risks, benefits and treatment alternatives of receiving invasive approach and he/she or his/her legally authorized representative provides written informed consent prior to any study related procedure.

Exclusion Criteria

* Hemodynamically unstable condition (SBP \<90 mmHg even after administration of vasopressor, ventricular arrhythmias, or cardiogenic shock)
* Known true anaphylaxis to contrast medium (not allergic reaction but anaphylactic shock)
* Known significant congenital, severe valvular or cardiomyopathic (hypertrophic or dilated cardiomyopathy, or any other forms) process which could explain cardiac symptoms.
* Severe left ventricular systolic dysfunction (ejection fraction \<30%)
* Intolerance to aspirin, clopidogrel, ticagrelor, prasugrel, or heparin.
* Non-cardiac co-morbid conditions are present with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment)
* Unwillingness or inability to comply with the procedures described in this protocol.

Where it's running

  • Samsung Medical Center
    Seoul, South Korea
    Recruiting
  • Chonnam National University Hospital
    Gwangju, South Korea
    Not yet recruiting
  • Chosun University Hospital
    Gwangju, South Korea
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.